RxDoctor Payments Data

Lana Hulbert

Family · Pittsburgh, PANPI 1750772646

Payments from drug & device makers

$13,347in general payments, 2019–2025

Across 892 payments — averaging $14.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • GSK$967
  • Amgen$895
  • plus $5K from 36 others

What the payments were for

  • Food & beverage$13,306100%
  • Education$420%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,347 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$14,410
Medicare patients
78
Services billed
166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide58$61,641
OzempicSemaglutide34$54,230
Trelegy ElliptaFluticasone/Umeclidin/Vilanter44$41,464
EliquisApixaban29$31,887
JardianceEmpagliflozin23$26,041
Xultophy 100-3.6Insulin Degludec/Liraglutide20$16,347
FarxigaDapagliflozin Propanediol13$15,392
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$15,141
Breo ElliptaFluticasone/Vilanterol23$13,045
Albuterol Sulfate HfaAlbuterol Sulfate90$3,015
Rosuvastatin Calcium165$2,097
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,956
Levothyroxine Sodium183$1,849
SynthroidLevothyroxine Sodium27$1,594
Duloxetine Hcl69$1,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Xultophy 100-3.6$1,527$70,57754 claims
Lilly USA, LLCMounjaro$1,116$61,64158 claims
GSKTrelegy Ellipta, Breo Ellipta$967$54,51067 claims
PfizerEliquis$1,161$31,88729 claims
AstraZenecaFarxiga, Breztri Aerosphere$287$30,53334 claims
Boehringer IngelheimJardiance$725$26,04123 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$1,849183 claims
AbbVieSynthroid$3,060$1,59427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →